Panelists discuss how treatment selection between combination immunotherapy (IO) and chemotherapy alone should favor the FDA-approved carboplatin-paclitaxel-retifanlimab regimen for most patients with ...

Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and ...

Gynecologic clear cell cancers are aggressive malignant neoplasms with low response rates to chemotherapy. Among patients with advanced clear cell ovarian and endometrial cancers who received ...

The European Commission (EC) has approved BeOne Medicines’ Tevimbra (tislelizumab) as part of a first-line combination ...

Analysts now project the global oncology drug market could surpass US$900 billion in revenue by 2034. Precedence Research ...

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy The following represents disclosure information provided by authors of this ...

BriaCell Therapeutics Corporation announces updated phase 2 data of Bria-IMT, shows survival advantage over Trodelvy in metastatic breast cancer: Philadelphia & Vancouver, British ...